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When Bruce Zetter called me late at night 
on January 14 with news of Judah Folk-
man’s passing, my shock and grief were 
almost as great as when I learned, 8 
years earlier, of my own father’s sudden 
death. I suspect many people shared my 
reaction, especially fellow researchers 
in the field of tumor angiogenesis. After 
all, he was widely acknowledged to be 
the father of the field, and a doting one 
at that, gently mentoring, encouraging, 
or guiding so many others along the way 
during his brilliant career.
In the days following Folkman’s death, 
hundreds of obituaries underscored his 
fame and reputation. Among many oth-
ers, The New York Times, Time, News-
week, Business Week, and The Wall 
Street Journal pointed out his importance 
to the field of cancer research. Under-
standably, and perhaps predictably, they 
primarily focused on his 1971 visionary 
hypothesis, first published in The 
New England Journal of Medi-
cine. He posited that avascular 
microscopic solid tumors must 
induce sustained formation of 
new blood vessels (a process 
termed angiogenesis) to achieve 
relentless growth and metastatic 
spread, doing so by producing 
a secretable circulating factor 
called TAF (tumor-angiogenesis 
factor). It should be possible, he 
reasoned, to develop “antiangio-
genesis” drugs (for example, an 
anti-TAF neutralizing antibody) to 
induce a state of tumor dormancy 
and hence prolong survival of 
cancer patients. The aforemen-
tioned obituaries emphasized the 
skepticism with which the sci-
entific community greeted these 
ideas and pointed out how Folk-
man doggedly persevered until 
finally he was vindicated more 
than 30 years later with the first 
clinical approval of a series of 
antiangiogenic drugs. The best 
known of these, approved in 
2004, is bevacizumab (Avastin), 
the anti-VEGF antibody used for 
the treatment of certain cancers and sub-
sequently a related anti-VEGF antibody 
for treating age-related macular degen-
eration (AMD), the most frequent cause of 
vision loss and blindness. Much was also 
made about his legendary generosity and 
humanity, especially with cancer patients 
and their families. He was a pediatric 
surgeon by training and was Surgeon-
in-Chief at Children’s Hospital in Boston 
for 14 years. Folkman often gave out his 
home phone number to patients’ families. 
He spent countless hours, usually late in 
the evening after work, providing advice—
and above all hope—to people he did not 
even know.
What these obituaries omitted, also 
understandably, were Folkman’s numer-
ous other scientific contributions, which 
not only advanced the field of tumor 
angiogenesis and antiangiogenic therapy 
but also laid crucial foundation stones for 
future discoveries. I think recounting these 
accomplishments here is important not 
only for their own sake but because too 
many researchers—especially younger 
ones in the field of tumor angiogene-
sis—do not appreciate the full extent of 
what Folkman accomplished. So here is 
a “top ten list” of Judah Folkman’s con-
ceptual and laboratory contributions in the 
field of tumor angiogenesis.
First is the brilliant and prescient 1971 
hypothesis based not only on his own 
basic tumor angiogenesis work at the 
time but also on the largely unsung find-
ings made by others, sometimes years 
earlier, which he cited in his classic 
paper. Back then the idea of a noncura-
tive therapy for cancer was heretical to 
most. Indeed, scientific as well as popu-
lar thinking of the era was summed up 
in 1972 when President Richard Nixon 
declared the “war on cancer” and set the 
goal of curing the disease within 
a decade. Today, the clinical goal 
of controlling advanced cancer in 
patients, rather than necessarily 
trying to completely eradicate it, 
is widely accepted.
Second, also in 1971, he 
reported a method to isolate 
a fraction of ascites fluid from 
tumor-bearing mice, which was 
competent to stimulate the for-
mation of new blood vessels. 
This discovery went hand-in-
hand with his more famous 1971 
paper. Third, in experiments that 
remain as beautiful today as when 
he published them in 1972 with 
Michael Gimbrone, a medical stu-
dent, Folkman showed that small 
tumor spheroids suspended in 
the avascular anterior chamber 
of the rabbit eye did not increase 
in size, but that they grew explo-
sively when relocated to another 
area (near the iris) where they 
were able to rapidly induce and 
attract new blood vessel capil-
laries. This work, an example of 
what some might derisively call 
“descriptive science,” supported 
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his 1971 theory that expansion of tumor 
mass is indeed dependent on angiogen-
esis. It became the bedrock for the theory 
of antiangiogenic therapy, namely that this 
treatment strategy can induce tumors to 
become dormant.
Fourth, beginning in 1974, Folkman 
contributed to the development of a series 
of assays to visualize and quantitatively 
measure angiogenesis. These included 
exploiting the chick egg chorioallan-
toic membrane (CAM) assay, published 
in 1979, in which pro- or antiangiogenic 
molecules or tumor cells could be placed 
alone or together in the CAM, where they 
induced or inhibited new blood vessel 
capillaries. He also helped pioneer the cor-
neal micropocket assay, initially in rabbits. 
First reported in 1974, it was later adapted 
for use in rodents, even mice. These in 
vivo assays were complimented by in vitro 
methods to grow human microvascular 
capillary endothelial cells and to study the 
sequential steps of blood vessel forma-
tion in a tissue culture dish. Folkman first 
reported this work in 1980 with Christian 
Haudenschild and Bruce Zetter.
Fifth, Folkman and Robert Langer, 
his first postdoctoral trainee, developed 
the methodology of sustained release 
of large molecules, including proteins, 
from implanted polymers. This seminal 
advance, reported in 1976, was used 
later, for example, in conjunction with the 
CAM or corneal micropocket assays, to 
establish gradients of angiogenic activity 
in vivo and helped launch the sustained 
release technology field in which Langer 
remains pre-eminent. Sixth, in a collab-
oration with his colleagues Yuen Shing 
and Michael Klagsbrun reported in 1983, 
the known affinity of some angiogen-
esis factors for heparin was elegantly 
exploited to isolate and then character-
ize the first tumor-cell-derived proangio-
genic stimulator, basic fibroblast growth 
factor (bFGF). This was another abso-
lutely seminal finding in the field.
Seventh, in 1982, beginning with 
protamine and platelet factor-4 (PF4), he 
and his team identified a whole series of 334 Cell 132, February 8, 2008 ©2008 Elsedifferent angiogenesis inhibitors. These 
included the fungal antibiotic fumagil-
lin (with Don Ingber), “angiostatic” ste-
roids, and endogenous proteins such as 
angiostatin and endostatin, which were 
used by him and many others around the 
world to study the principles of antian-
giogenic cancer therapy.
Eighth, with Robert D’Amato in the 
early 1990s he began to study what I have 
called “accidental” antiangiogenic drugs, 
such as thalidomide. This work led directly 
to the successful use of thalidomide and 
several of its analogs for the treatment 
of patients with multiple myeloma. Folk-
man was also instrumental in suggesting 
the successful treatment of rare but life-
threatening hemangiomas in infants and 
children by using prolonged courses of 
daily low-dose interferon injections. Ninth, 
with Tim Browder, a young research fel-
low, Folkman developed the concept of 
frequent low-dose, minimally toxic “met-
ronomic” chemotherapy as an antiangio-
genic therapy strategy that could have 
an impact even when used to treat drug-
resistant tumors in mice. He shared these 
findings with me 2 years prior to their pub-
lication in 2000—another reflection of his 
renowned openness and generosity, and 
which had a seminal impact on the direc-
tion my own tumor angiogenesis research 
program would subsequently take. Finally, 
with Noel Weider, he pioneered the idea of 
quantitating microvessel density in tumors 
as a prognostic indicator. These elegant 
studies alerted many basic researchers 
and oncologists—not just pathologists—to 
the extent that tumors can become infil-
trated by blood vessels.
Folkman’s enormous and enduring 
impact on the field extended far beyond 
these and his many other discoveries, 
impressive as they are. He was a magical 
lecturer. His presentations were models 
of scientific clarity, perfectly punctuated 
with wit, humor, and brilliant philosophi-
cal insights. Not surprisingly, he was the 
recipient of numerous teaching awards 
over the many years he taught at Harvard 
Medical School. He seemed incapable of vier Inc.turning down any invitation to give a lec-
ture, no matter where it was. He must have 
given thousands during his career. Thus, 
numerous young physicians and research-
ers—and older ones as well—listened to 
him discuss his research and present his 
provocative ideas. I often wonder how 
many of the angiogenesis researchers 
today—it is estimated that there are now 
about a thousand angiogenesis labora-
tories worldwide—were inspired to enter 
the field simply by hearing him speak. He 
was also a wonderful and inspiring men-
tor to so many younger investigators, not 
just those in his laboratory or the vascular 
biology program he directed at Children’s 
Hospital in Boston but also to countless 
others entering the field elsewhere. Folk-
man never viewed new researchers enter-
ing his field as competitors. Instead, he 
welcomed them as future colleagues who 
shared the common goal of using antian-
giogenic therapy to improve the lives of 
patients with cancer and other debilitating 
conditions caused by pathological angio-
genesis. His mentoring of others extended 
to family life. By example, he showed that 
one can work impossibly hard as a scien-
tist without sacrificing the needs of fam-
ily members. Lovingly married to his wife 
Paula for 47 years, he was a devoted hus-
band, father, grandfather, and brother.
Judah Folkman’s remarkable achieve-
ments were recognized with a huge num-
ber of prestigious research awards and 
named lectureships. He had 19 honorary 
degrees. He was elected in 1990 to the 
National Academy of Sciences and the 
Institute of Medicine. He was also a mem-
ber of the American Academy of Arts and 
Sciences as well as the American Philo-
sophical Society. But of all the awards 
he received, it is said that the one he was 
most proud of was the 2006 Helen Keller 
Prize for Vision Research, a highly coveted 
award in ophthalmology. How fitting for 
someone who was such a visionary, and 
who opened the eyes of so many investi-
gators around the world to the excitement 
and possibilities of angiogenesis research 
for the good of mankind.
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